Literature DB >> 34015090

Reply to Lapadula et al.

Rebecca N Kumar1, En-Ling Wu1, Valentina Stosor1,2, William J Moore3, Chad Achenbach1,4, Michael G Ison1,2, Michael P Angarone1.   

Abstract

Entities:  

Year:  2022        PMID： 34015090      PMCID： PMC8800173          DOI： 10.1093/cid/ciab468

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


× No keyword cloud information.
  6 in total

1.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

2.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

3.  Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.

Authors:  Rebecca N Kumar; En-Ling Wu; Valentina Stosor; William J Moore; Chad Achenbach; Michael G Ison; Michael P Angarone
Journal:  Clin Infect Dis       Date:  2022-01-07       Impact factor: 9.079

4.  Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.

Authors:  Robert L Gottlieb; Ajay Nirula; Peter Chen; Joseph Boscia; Barry Heller; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Princy Kumar; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Michael Durante; Gerard Oakley; Andrew E Schade; Timothy R Holzer; Philip J Ebert; Richard E Higgs; Nicole L Kallewaard; Janelle Sabo; Dipak R Patel; Paul Klekotka; Lei Shen; Daniel M Skovronsky
Journal:  JAMA       Date:  2021-02-16       Impact factor: 56.272

5.  Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  J Ryan Bariola; Erin K McCreary; Richard J Wadas; Kevin E Kip; Oscar C Marroquin; Tami Minnier; Stephen Koscumb; Kevin Collins; Mark Schmidhofer; Judith A Shovel; Mary Kay Wisniewski; Colleen Sullivan; Donald M Yealy; David A Nace; David T Huang; Ghady Haidar; Tina Khadem; Kelsey Linstrum; Christopher W Seymour; Stephanie K Montgomery; Derek C Angus; Graham M Snyder
Journal:  Open Forum Infect Dis       Date:  2021-05-17       Impact factor: 3.835

6.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

Authors:  Peter Chen; Ajay Nirula; Barry Heller; Robert L Gottlieb; Joseph Boscia; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Lei Shen; Michael Durante; Gerard Oakley; Andrew E Schade; Janelle Sabo; Dipak R Patel; Paul Klekotka; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2020-10-28       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.